Loading stock data…
Lantern Pharma Inc (LTRN)
$1.84-0.06 (-3.41%)
Market ClosedLast close Sep 8
Lantern Pharma Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lantern Pharma Inc. in the Healthcare sector is trading at $1.84 with a market capitalization of $48M. Wall Street consensus targets $17.50 (2 analysts), implying a +851.1% move over the next 12 months. The stock is currently 61% below its 52-week high of $4.70, remaining 37.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +851.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 15) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.41M↑ | -$4.20M↑ | -$4.35M↑ | -$4.65M↑ | -$4.77M |
| Net Income | -$3.33M↑ | -$4.07M↑ | -$4.18M↑ | -$4.33M↑ | -$4.54M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma;...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$47.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-461.79%
Volume
Today's trading volume
242,570
Recent News
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
LP-300 shows strong efficacy in lung cancer while operating losses shrink 25%.
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ...
Lantern Pharma reports promising LP-300 data and launches Open Medicine AI spin-out while managing a tighter cash position.
Lantern Pharma Inc. Q2 2026 Earnings Call Summary
Moby summary of Lantern Pharma Inc.'s Q2 2026 earnings call
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript
Need a quote from a Motley Fool analyst? Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in our annual report on Form 10-K for the year ended December 31, 2024, which is on file with the SEC and available on our website.
Promising Penny Stocks To Consider In May 2026
The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. Penny stocks, while an older term, continue to capture attention as they often represent smaller or newer companies that provide growth opportunities at lower price points. By focusing on those with strong financial health and solid fundamentals, investors can uncover...